Chain of two or more amino acids linked together with peptide bond is referred as peptide. Peptide bond is a unique bond with linkage of carboxyl carbon atom of one amino acid to nitrogen atom of another amino acid in the chain. Two different methods namely solid phase peptide synthesis (SPPS) and liquid phase peptide synthesis (LPPS) are used for synthesis of peptides. Peptides are classified based on the number of amino acids present in the chain. Presence of fifty or more amino acids in a chain formulates a protein molecule.
Peptides are widely used in medicines and biotechnology. Peptides act as an endocrine signal or a neurotransmitter to regulate most of the physiological processes. Peptides are potential molecules for treating many disease conditions such as diabetes. Currently, 60 peptide drugs are approved by the U.S. Food and Drug Administration (FDA). In addition, over five hundred peptide drug molecules are in pre clinical trials and 140 peptide drug molecules are in the clinical trials. Use of peptides for treating various infections is under development and many key players are involved in the process. Based on the type of infections, the global anti-infective peptides market is classified as follows:
- Anti-Bacterial Peptides
- Anti-Viral Peptides
- Anti-Fungal Peptides
- Anti-Microbial Peptides
- Anti-Parasitic Peptides
- Anti-HIV Peptides
Infections such as gram positive and gram negative infections, complicated skin and skin structure infections (cSSSI), gingivitis, otitis media and catheter associated infection are treated with anti-bacterial peptides. Infections such as vaginal infection, oral candida infections, and oesophageal candidiasis are treated using anti-fungal peptides. Anti-viral peptides are used to treat viral infections caused by human immunodeficiency virus (HIV), hepatitis C virus (HCV) and H5N1 stains.
Geographically, the global anti-infective peptides market is segmented into North America, Europe, Asia Pacific and Rest of the World (RoW) regions. North America comprises anti-infective peptides market for the U.S and Canada. Europe comprises cumulative market of anti-infective peptides in Germany, Italy, France, Spain, and Rest of Europe (RoE). Asia Pacific comprises cumulative market of anti-infective peptides in China, India, Australia, New Zealand and rest of Asia Pacific (RoAPAC). Rest of the World (RoW) comprises anti-infective peptides market in Latin America, Middle East and Russia. Presently, North America is dominating the global anti-infective peptides market. Europe is the second largest market of anti-infective peptides after North America.
Factors such as highly developed healthcare infrastructure, availability of advanced research and development facilities, government funds for research activities in the field of healthcare and biotechnology and well structured regulatory framework are driving the growth of the anti-infective peptides market in North America and Europe. Asia Pacific is anticipated to be fastest growing market for anti-infective peptides. Factors such as rapidly developing healthcare infrastructure on the grounds of emerging medical tourism industry in this region coupled with government initiative to boost biotechnology sector of the respective country are fueling the growth of the anti-infective peptides market in Asia Pacific region.
Some of the key players involved in the development of anti-infective peptides include Theravance Biopharma, Actavis plc, ANI Pharmaceuticals, Adamis Pharmaceuticals, AstraZeneca plc, Cantab Biopharmaceuticals, Dipexium Pharmaceuticals, Immunotech Laboratories, Nanotides Pharmaceuticals, Novartis International AG and Pfizer, Inc.